| Identification | Back Directory | [Name]
N-[3-(1H-benzimidazol-2-yl)-4-chlorophenyl]pyridine-3-carboxamide | [CAS]
496793-75-0 | [Synonyms]
AZSMO23
AZSMO-23
AZSMO 23
N-[3-(1H-benzimidazol-2-yl)-4-chlorophenyl]pyridine-3-carboxamide | [Molecular Formula]
C19H13ClN4O | [MOL File]
496793-75-0.mol | [Molecular Weight]
348.79 |
| Hazard Information | Back Directory | [Description]
AZSMO-23 is an activator of the human ether-a-go-go-related gene (hERG)-encoded potassium channel (Kv11.1). It acts by blocking hKv4.3-hKChIP2.2, hCav3.2 and hKv1.5 and activating hCav1.2/β2/α2δ. | [Uses]
AZSMO-23 is a potent hERG K+ channel activator. AZSMO-23 activats WT hERG pre-pulse and tail current with EC50 values of 28.6, 11.2 μM, respectively. AZSMO-23 has the potential for the research of long QT syndrome[1]. | [References]
[1] Mannikko R, et al. Pharmacological and electrophysiological characterization of AZSMO-23, an activator of the hERG K(+) channel. Br J Pharmacol. 2015 Jun;172(12):3112-25. DOI:10.1111/bph.13115 |
|
| Company Name: |
PHARMEKS Ltd.
|
| Tel: |
+7 (495) 702-9648 |
| Website: |
www.pharmeks.com |
|